|

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

RECRUITINGPhase 3Sponsored by Corbus Pharmaceuticals Inc.
Actively Recruiting
PhasePhase 3
SponsorCorbus Pharmaceuticals Inc.
Started2026-09-29
Est. completion2027-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations38 sites

Summary

The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum based chemotherapy or immunotherapy (using a check-point inhibitor) It will also learn about the safety of the drug and measure quality of life. The main questions it asks are: * What proportion of participants respond to CRB-701 measured using scans (CT or MRI) * What medical problems do participants experience when taking CRB-701. Researchers will compare CRB-701 with standard of care medicines (drugs that are normally used this disease). Participants will: * Attend clinic every three weeks to receive infusions of CRB-701 or standard of care medicines until the cancer cannot be measured or is not controlled by the treatment they are receiving. * Have a CT or MRI every 6 weeks to measure the effect on their cancer * Complete questionnaires to assess their health status.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histological and/or cytological confirmed diagnosis of OPSCC arising from tonsils, base of tongue, soft palate and posterior pharyngeal wall, with evidence of metastatic or recurrent disease not amenable to standard therapy with curative intent.
* Either second or third-line OPSCC patients who have progressed on or after receiving SOC therapy (that must have included platinum chemotherapy and an anti-PD-(L)1 antibody administered sequentially or together) OR received platinum chemotherapy and/or anti-PD-(L)1 therapy in the neoadjuvant or adjuvant setting or as part of definitive chemoradiation therapy, provided disease recurrence occurred less than 6 months after completion of the relevant systemic therapy.
* ECOG PS of 0-1
* Measurable disease as per RECIST v1.1, with at least one measurable lesion not previously irradiated unless unequivocal progression has been documented after radiation.
* Life expectancy of greater than 12 weeks at time of enrollment, as per Investigator's assessment.

Signed informed consent

Exclusion Criteria:

* Persistent CTCAE Grade \>1 clinically significant toxicities related to prior antineoplastic therapies, excluding alopecia.
* Significant active or chronic corneal disorders
* Pre-existing Grade ≥2 peripheral neuropathy
* Any other significant co-morbidities, disease, metabolic dysfunction, physical examination, or clinical laboratory finding that contraindicates the use of the investigational drug or may represent an unacceptable risk from treatment complications or may affect adherence to the study procedures or the interpretation of the results.
* Pregnant or breastfeeding females

Conditions2

CancerOropharyngeal Carcinoma (OPC)

Interventions4

Locations38 sites

Clearview Cancer Institute
Huntsville, Alabama, 38505
Clinical Study Coordinator1+ (888)- 374-1015clinical@corbuspharma.com
The University of Arizona Cancer Center
Tucson, Arizona, 85719
Clinical Study Coordinator+1-(520)-654-2873UACC-Clinicaltrialsinfo@arizona.edu
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Clinical Study Coordinator+1 (877)-405-2009clinical@corbuspharma.com
University of California Los Angeles Westwood Cancer Center
Clinical Study Coordinator+1-(310)-794-4955clinical@corbuspharma.com
Stanford Medicine - Cancer Center
Palo Alto, California, 94304
Clinical Study Coordinator+1-(833)-444-7622clinical@corbuspharma.com

Find trials near these locations

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.